GlassScriptPhysician profile
Melissa M Lane
NPI 1336905850
$1,301.31
in general payments reported to CMS, 2019-2025
12 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $868 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,301.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $344.38 | 2024-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $240.39 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $186.82 | 2024-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $100.49 | 2024-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $95.72 | 2024-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $90.41 | 2024-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $82.19 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $62.01 | 2024-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $29.87 | 2024 | |
| Indivior INC. | $27.07 | 2024 | Perseris |
| Supernus Pharmaceuticals, INC. | $26.75 | 2024 | Qelbree |
| Abbvie INC. | $15.21 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Lane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.